TY - JOUR
T1 - Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation
T2 - Results from South Australian clinical registry for advanced colorectal cancer
AU - Khattak, Muhammad A.
AU - Martin, Hilary L.
AU - Beeke, Carol
AU - Price, Timothy
AU - Carruthers, Scott
AU - Kim, Susan
AU - Padbury, Robert
AU - Karapetis, Christos S.
N1 - Funding Information:
Financial support was provided by an Enabling educational grant for the SA Cancer Registry in 2006 from Sanofi-Aventis , Australia; no grant was received since 2009.
PY - 2012/12
Y1 - 2012/12
N2 - Background: Colorectal cancer is the third most common cancer in Australia. The median overall survival for metastatic colorectal cancer is nearly 2 years. However, there may be survival differences based on site of metastatic disease. Methods: Data was collected from the South Australian Registry for Advanced Colorectal Cancer. A total of 1207 patients with single site metastatic disease at initial diagnosis were subclassified into 6 subgroups: liver only (n = 780), pelvic only (n = 148), lung only (n = 142), lymph node only (n = 95), bone only (n = 32), and brain only (n = 10). Univariate and multivariate parametric survival analyses were performed. Results: Median overall survival was 20.3 months for the whole group. The overall survival for lung-only metastases group was 41.1 months followed by liver- and pelvic-only disease groups (22.8 and 23.8 months, respectively). Patients with isolated bone-only and brain-only metastases had poor overall survival (5.1 and 5.7 months, respectively). On multivariate analysis, prognosis was superior for the lung-only group. Conclusions: Lung only group had the longest median overall survival. Bone and brain sites had a poor outlook. Site of metastatic disease at initial presentation may be prognostic.
AB - Background: Colorectal cancer is the third most common cancer in Australia. The median overall survival for metastatic colorectal cancer is nearly 2 years. However, there may be survival differences based on site of metastatic disease. Methods: Data was collected from the South Australian Registry for Advanced Colorectal Cancer. A total of 1207 patients with single site metastatic disease at initial diagnosis were subclassified into 6 subgroups: liver only (n = 780), pelvic only (n = 148), lung only (n = 142), lymph node only (n = 95), bone only (n = 32), and brain only (n = 10). Univariate and multivariate parametric survival analyses were performed. Results: Median overall survival was 20.3 months for the whole group. The overall survival for lung-only metastases group was 41.1 months followed by liver- and pelvic-only disease groups (22.8 and 23.8 months, respectively). Patients with isolated bone-only and brain-only metastases had poor overall survival (5.1 and 5.7 months, respectively). On multivariate analysis, prognosis was superior for the lung-only group. Conclusions: Lung only group had the longest median overall survival. Bone and brain sites had a poor outlook. Site of metastatic disease at initial presentation may be prognostic.
KW - Chemotherapy
KW - Colorectal
KW - Metastasis
KW - Registry
KW - Surgery
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=84868111722&partnerID=8YFLogxK
U2 - 10.1016/j.clcc.2012.06.004
DO - 10.1016/j.clcc.2012.06.004
M3 - Article
C2 - 22763194
AN - SCOPUS:84868111722
SN - 1533-0028
VL - 11
SP - 247
EP - 254
JO - Clinical Colorectal Cancer
JF - Clinical Colorectal Cancer
IS - 4
ER -